{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:05:41Z","timestamp":1784106341102,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101097094"],"award-info":[{"award-number":["101097094"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is an incurable malignancy, marked by treatment resistance and frequent relapses, posing ongoing challenges to patients\u2019 long-term management. Herein, we have examined tRNA-derived small RNA fragments (3\u2032U-tRFs), generated from precursor tRNAs, to identify MM-related 3\u2032U-tRFs in ameliorating MM precision prognostics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      3\u2032U-tRF profiles were generated by small RNA-seq data. Target prediction and gene ontology analysis were assessed by tRFtarget and DAVID databases, respectively. CD138\u2009+\u20093\u2032U-tRF\n                      <jats:sup>SerTGA<\/jats:sup>\n                      levels were quantified in our MM screening cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009136 patients) by RT-qPCR. Kaplan\u2013Meier and Cox proportional regression analyses were performed, using disease progression and patients\u2019 mortality as clinical endpoints. Internal validation was conducted by bootstrap Cox regression while clinical benefit on patients\u2019 prognosis was assessed by decision curve analysis (DCA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Small RNA-seq data analysis highlighted the significantly increased 3\u2032U-tRF\n                      <jats:sup>SerTGA<\/jats:sup>\n                      levels in MM cell lines compared to normal cells (FC: 14.03). Our screening cohort confirmed the significantly higher risk for short-term progression and worse survival of the patients presenting elevated 3\u2032U-tRF\n                      <jats:sup>SerTGA<\/jats:sup>\n                      . 3\u2032U-tRF\n                      <jats:sup>SerTGA<\/jats:sup>\n                      -fitted multivariate models demonstrated superior risk-stratification of the patients for treatment response and prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study indicate the elevated 3\u2032U-tRF\n                      <jats:sup>SerTGA<\/jats:sup>\n                      as a strong independent predictor of poor first-line chemotherapy outcomes and MM progression, providing refined stratification of patient risk.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03447-5","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:38:11Z","timestamp":1777898291000},"page":"470-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3\u2032U-tRFSerTGA leads to poor disease prognosis"],"prefix":"10.1038","volume":"135","author":[{"given":"Konstantinos","family":"Soureas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Alexandra","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina-Marina","family":"Pilala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine-Ivy","family":"Liacos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-4949","authenticated-orcid":false,"given":"Andreas","family":"Scorilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-9886","authenticated-orcid":false,"given":"Margaritis","family":"Avgeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"3447_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3447_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Prim. 2024;10:45.","journal-title":"Nat Rev Dis Prim"},{"key":"3447_CR3","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","volume":"78","author":"N van Nieuwenhuijzen","year":"2018","unstructured":"van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78:2449\u201356.","journal-title":"Cancer Res"},{"key":"3447_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"3447_CR5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"3447_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"3447_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3324\/haematol.2016.145078","volume":"102","author":"E Kastritis","year":"2017","unstructured":"Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102:593\u20139.","journal-title":"Haematologica"},{"key":"3447_CR8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00277-018-3316-7","volume":"97","author":"V Gonzalez-Calle","year":"2018","unstructured":"Gonzalez-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, et al. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018;97:1453\u201362.","journal-title":"Ann Hematol"},{"key":"3447_CR9","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"3447_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1735","volume":"14","author":"MA Papadimitriou","year":"2023","unstructured":"Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, Avgeris M. Epi-miRNAs: modern mediators of methylation status in human cancers. Wiley Interdiscip Rev RNA. 2023;14:e1735.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"3447_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.molmed.2023.07.003","volume":"29","author":"K Soureas","year":"2023","unstructured":"Soureas K, Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, Avgeris M. Cancer quiescence: non-coding RNAs in the spotlight. Trends Mol Med. 2023;29:843\u201358.","journal-title":"Trends Mol Med"},{"key":"3447_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01248-2","volume":"15","author":"K Soureas","year":"2025","unstructured":"Soureas K, Malandrakis P, Papadimitriou MA, Minopoulos C, Ntanasis-Stathopoulos I, Liacos CI, et al. Refining precision prognostics in multiple myeloma: loss of miR-221\/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome. Blood Cancer J. 2025;15:41.","journal-title":"Blood Cancer J"},{"key":"3447_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.tibs.2016.05.004","volume":"41","author":"P Kumar","year":"2016","unstructured":"Kumar P, Kuscu C, Dutta A. Biogenesis and function of transfer RNA-related fragments (tRFs). Trends Biochem Sci. 2016;41:679\u201389.","journal-title":"Trends Biochem Sci"},{"key":"3447_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.997780","volume":"13","author":"S George","year":"2022","unstructured":"George S, Rafi M, Aldarmaki M, ElSiddig M, Al Nuaimi M, Amiri KMA. tRNA derived small RNAs-Small players with big roles. Front Genet. 2022;13:997780.","journal-title":"Front Genet"},{"key":"3447_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2019.03.012","volume":"452","author":"L Zhu","year":"2019","unstructured":"Zhu L, Ge J, Li T, Shen Y, Guo J. tRNA-derived fragments and tRNA halves: the new players in cancers. Cancer Lett. 2019;452:31\u20137.","journal-title":"Cancer Lett"},{"key":"3447_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.febslet.2008.12.043","volume":"583","author":"H Fu","year":"2009","unstructured":"Fu H, Feng J, Liu Q, Sun F, Tie Y, Zhu J, et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett. 2009;583:437\u201342.","journal-title":"FEBS Lett"},{"key":"3447_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53624-4","volume":"15","author":"H Jin","year":"2024","unstructured":"Jin H, Yeom JH, Shin E, Ha Y, Liu H, Kim D, et al. 5\u2019-tRNA(Gly(GCC)) halves generated by IRE1alpha are linked to the ER stress response. Nat Commun. 2024;15:9273.","journal-title":"Nat Commun"},{"key":"3447_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/wrna.64","volume":"2","author":"RJ Maraia","year":"2011","unstructured":"Maraia RJ, Lamichhane TN. 3\u2019 processing of eukaryotic precursor tRNAs. Wiley Interdiscip Rev RNA. 2011;2:362\u201375.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"3447_CR19","doi-asserted-by":"publisher","first-page":"e10563","DOI":"10.1371\/journal.pone.0010563","volume":"5","author":"JY Liao","year":"2010","unstructured":"Liao JY, Ma LM, Guo YH, Zhang YC, Zhou H, Shao P, et al. Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3\u2019 trailers. PLoS ONE. 2010;5:e10563.","journal-title":"PLoS ONE"},{"key":"3447_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01739-5","volume":"22","author":"M Fu","year":"2023","unstructured":"Fu M, Gu J, Wang M, Zhang J, Chen Y, Jiang P, et al. Emerging roles of tRNA-derived fragments in cancer. Mol Cancer. 2023;22:30.","journal-title":"Mol Cancer"},{"key":"3447_CR21","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2010-05-285403","volume":"116","author":"DD Jima","year":"2010","unstructured":"Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 2010;116:e118\u201327.","journal-title":"Blood"},{"key":"3447_CR22","doi-asserted-by":"publisher","first-page":"D141","DOI":"10.1093\/nar\/gku1138","volume":"43","author":"P Kumar","year":"2015","unstructured":"Kumar P, Mudunuri SB, Anaya J, Dutta A. tRFdb: a database for transfer RNA fragments. Nucleic Acids Res. 2015;43:D141\u20135.","journal-title":"Nucleic Acids Res"},{"key":"3447_CR23","doi-asserted-by":"publisher","first-page":"D254","DOI":"10.1093\/nar\/gkaa831","volume":"49","author":"N Li","year":"2021","unstructured":"Li N, Shan N, Lu L, Wang Z. tRFtarget: a database for transfer RNA-derived fragment targets. Nucleic Acids Res. 2021;49:D254\u2013D60.","journal-title":"Nucleic Acids Res"},{"key":"3447_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W da Huang","year":"2009","unstructured":"da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44\u201357.","journal-title":"Nat Protoc"},{"key":"3447_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-8-53","volume":"8","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inf Decis Mak. 2008;8:53.","journal-title":"BMC Med Inf Decis Mak"},{"key":"3447_CR26","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1073\/pnas.1604266113","volume":"113","author":"Y Pekarsky","year":"2016","unstructured":"Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, et al. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci USA. 2016;113:5071\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3447_CR27","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.1073\/pnas.1706908114","volume":"114","author":"V Balatti","year":"2017","unstructured":"Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, et al. tsRNA signatures in cancer. Proc Natl Acad Sci USA. 2017;114:8071\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3447_CR28","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1101\/gad.1837609","volume":"23","author":"YS Lee","year":"2009","unstructured":"Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev. 2009;23:2639\u201349.","journal-title":"Genes Dev"},{"key":"3447_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216701","volume":"587","author":"Q Chen","year":"2024","unstructured":"Chen Q, Li D, Jiang L, Wu Y, Yuan H, Shi G, et al. Biological functions and clinical significance of tRNA-derived small fragment (tsRNA) in tumors: current state and future perspectives. Cancer Lett. 2024;587:216701.","journal-title":"Cancer Lett"},{"key":"3447_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04930-6","volume":"13","author":"H Cui","year":"2022","unstructured":"Cui H, Li H, Wu H, Du F, Xie X, Zeng S, et al. A novel 3\u2019tRNA-derived fragment tRF-Val promotes proliferation and inhibits apoptosis by targeting EEF1A1 in gastric cancer. Cell Death Dis. 2022;13:471.","journal-title":"Cell Death Dis"},{"key":"3447_CR31","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41388-024-02991-9","volume":"43","author":"Q Xiong","year":"2024","unstructured":"Xiong Q, Zhang Y, Xu Y, Yang Y, Zhang Z, Zhou Y, et al. tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c\u2011MYC transcription. Oncogene. 2024;43:1274\u201387.","journal-title":"Oncogene"},{"key":"3447_CR32","doi-asserted-by":"crossref","unstructured":"Papadimitriou MA, Avgeris M, Levis P, Papasotiriou EC, Kotronopoulos G, Stravodimos K, et al. tRNA-derived fragments (tRFs) in bladder cancer: increased 5\u2019-tRF-LysCTT results in disease early progression and patients\u2019 poor treatment outcome. Cancers. 2020;12:3661.","DOI":"10.3390\/cancers12123661"},{"key":"3447_CR33","doi-asserted-by":"crossref","unstructured":"Panoutsopoulou K, Dreyer T, Dorn J, Obermayr E, Mahner S, Gorp TV, et al. tRNA(GlyGCC)-derived internal fragment (i-tRF-GlyGCC) in ovarian cancer treatment outcome and progression. Cancers. 2021;14:24.","DOI":"10.3390\/cancers14010024"},{"key":"3447_CR34","doi-asserted-by":"publisher","first-page":"24766","DOI":"10.18632\/oncotarget.8293","volume":"7","author":"M Olvedy","year":"2016","unstructured":"Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova ES. A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget. 2016;7:24766\u201377.","journal-title":"Oncotarget"},{"key":"3447_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2022.11.033","volume":"180","author":"K Panoutsopoulou","year":"2023","unstructured":"Panoutsopoulou K, Magkou P, Dreyer T, Dorn J, Obermayr E, Mahner S, et al. tRNA-derived small RNA 3\u2019U-tRF(ValCAC) promotes tumour migration and early progression in ovarian cancer. Eur J Cancer. 2023;180:134\u201345.","journal-title":"Eur J Cancer"},{"key":"3447_CR36","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1002\/jcp.29419","volume":"235","author":"NH Farina","year":"2020","unstructured":"Farina NH, Scalia S, Adams CE, Hong D, Fritz AJ, Messier TL, et al. Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer. J Cell Physiol. 2020;235:5318\u201327.","journal-title":"J Cell Physiol"},{"key":"3447_CR37","doi-asserted-by":"publisher","first-page":"24252","DOI":"10.1073\/pnas.1913695116","volume":"116","author":"D Veneziano","year":"2019","unstructured":"Veneziano D, Tomasello L, Balatti V, Palamarchuk A, Rassenti LZ, Kipps TJ, et al. Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2019;116:24252\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3447_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8708312","volume":"2022","author":"J Ren","year":"2022","unstructured":"Ren J, Wu X, Shang FF, Qi Y, Tang Z, Wen C, et al. The tRNA-Cys-GCA derived tsRNAs suppress tumor progression of gliomas via regulating VAV2. Dis Markers. 2022;2022:8708312.","journal-title":"Dis Markers"},{"key":"3447_CR39","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/bjh.19332","volume":"204","author":"K Soureas","year":"2024","unstructured":"Soureas K, Papadimitriou MA, Malandrakis P, Papanota AM, Adamopoulos PG, Ntanasis-Stathopoulos I, et al. Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: loss of mitochondrial i-tRF(HisGTG) results in patients\u2019 poor treatment outcome. Br J Haematol. 2024;204:1790\u2013800.","journal-title":"Br J Haematol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03447-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:30:32Z","timestamp":1784104232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03447-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,5]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03447-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the 1975 Declaration of Helsinki ethical standards, as revised in 2008, and approved by the Ethics Committee of \u2018Alexandra\u2019 Hospital, Athens, Greece.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained by all patients participating.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Ethics"}}]}}